Zou Weiyan, Yang Yan, Zheng Rongsheng, Wang Zishu, Zeng Huihui, Chen Zhelong, Yang Fen, Wang Junbin
Department of Histology and Embryology, Bengbu Medical College Bengbu 233004, Anhui Province, China.
Department of Oncology, The First Affiliated Hospital of Bengbu Medical College Bengbu 233004, Anhui Province, China.
Int J Clin Exp Pathol. 2020 May 1;13(5):1008-1016. eCollection 2020.
CD44CD24 phenotypes are associated with poor outcome of triple-negative breast cancer (TNBC); however, the role of the CD44CD24 phenotype in lymph node metastasis and survival has not been fully understood in TNBC.
A total of 51 TNBC patients were included. CD44 and CD24 expression was determined using immunohistochemistry by which CD44 and CD24 were double-immunostained. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method.
The proportion of the CD44CD24 phenotype was 33.3% in TNBC specimens without lymph node metastases and 69.0% in those with lymph node metastases. In addition, the CD44CD24 phenotype correlated significantly with tumor size, histologic classification, TNM stage, and lymph node metastasis ( < 0.05). The CD44CD24 phenotype was detected in 69.0% of TNBC patients with lymph node metastases, and 51.7% of TNBC patients without lymph node metastases. In TNBC patients without lymph node metastases, the median DFS and OS were 18.2 and 28 months in cases with a CD44CD24 phenotype and 26.5 and 42.5 months in those without a CD44CD24 phenotype ( < 0.05), and in TNBC patients with lymph node metastases, the median DFS and OS were 17.2 and 25.7 months in cases with a CD44CD24 phenotype and 24.5 and 39.3 months in those without a CD44CD24 phenotype, respectively ( < 0.05).
CD44 and CD24 are independent prognostic markers for patients with TNBC. The CD44CD24 phenotype correlates with more aggressive clinicopathologic features and is strongly associated with poor prognosis in patients with TNBC.
CD44CD24表型与三阴性乳腺癌（TNBC）的不良预后相关；然而，CD44CD24表型在TNBC淋巴结转移和生存中的作用尚未完全明确。
共纳入51例TNBC患者。采用免疫组织化学法检测CD44和CD24表达，对CD44和CD24进行双重免疫染色。采用Kaplan-Meier法估计总生存期（OS）和无病生存期（DFS）。
在无淋巴结转移的TNBC标本中，CD44CD24表型的比例为33.3%，在有淋巴结转移的标本中为69.0%。此外，CD44CD24表型与肿瘤大小、组织学分类、TNM分期和淋巴结转移显著相关（P<0.05）。在有淋巴结转移的TNBC患者中，69.0%检测到CD44CD24表型，在无淋巴结转移的TNBC患者中，51.7%检测到该表型。在无淋巴结转移的TNBC患者中，有CD44CD24表型的患者中位DFS和OS分别为18.2个月和28个月，无CD44CD24表型的患者分别为26.5个月和42.5个月（P<0.05）；在有淋巴结转移的TNBC患者中，有CD44CD24表型的患者中位DFS和OS分别为17.2个月和25.7个月，无CD44CD24表型的患者分别为24.5个月和39.3个月（P<0.05）。
CD44和CD24是TNBC患者独立的预后标志物。CD44CD24表型与更具侵袭性的临床病理特征相关，且与TNBC患者的不良预后密切相关。
